Zacks Investment Research
01 Apr 2026, 12:55 UTC · 25w ago
Verdict
Headline takes no side. We score APLS +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Biogen has announced a $5.6 billion all-cash acquisition of Apellis Pharmaceuticals at $41 per share.
More positive than 99% of claims this week
Apellis Pharmaceuticals' two approved drugs, Empaveli and Syfovre, generated $689 million in 2025 revenue.
So whatConfirmed revenue streams provide the fundamental valuation support for the acquisition price.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 64% of claims this week
Apellis Pharmaceuticals is expected to report a quarterly loss of $0.38 per share and revenue of $200.75 million in its upcoming report.
More negative than 65% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Shares rallied 135.4% following a $5.6 billion acquisition announcement at a significant premium.
More positive than 64% of ticker scores this week
Acquiring Apellis Pharmaceuticals is expected to provide meaningful EPS accretion and long-term growth potential.
More positive than 53% of ticker scores this week
The stock finished the last trading session 8.7% higher.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
More positive than 2% of relationship scores this week
[mutual] Both companies are identified as members of the Zacks Medical - Biomedical and Genetics industry.
+2.0%
Price agrees with the score
$41.03 vs $40.23 close before publication (Mar 31) · not market-adjusted
APLS chart →
